CompletedEarly Phase 1

Comparison of Intradermal Microinjections of Tanexamic Acid and Oral Tranexamic Acid in the Management of Melasma.

Pakistan218 participantsStarted 2024-11-14

Plain-language summary

In this study we compared the effect of intradermal microinjections of tranexamic acid vs oral tranexamic acid in treatment of melasma. Given the high prevalence of melasma in Pakistan and the significant psychosocial impact on patients, particularly in Peshawar, this study will provide valuable insights into optimal treatment strategies

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients aged 18 to 55 years, with clinically confirmed melasma of at least 6 months duration.
✓. Fitzpatrick skin types III-V and no active dermatological conditions in the treatment area.

Exclusion criteria

✕. pregnancy or lactation
✕. History of thromboembolic disorders
✕. Use of hormonal therapies or photosensitizing medications
✕. Recent melasma treatments within the past 3 months
✕. Known hypersensitivity to tranexamic acid.

What they're measuring

Assessment of Melasma Area and Severity Index

Timeframe: Six months

Trial details

NCT IDNCT07280234

SponsorHayat Abad Medical Complex, Peshawar

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-05-15

View on ClinicalTrials.gov More Melasma trials